<DOC>
	<DOCNO>NCT01288261</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bavituximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving paclitaxel together bavituximab may kill tumor cell . PURPOSE : This phase I trial study side effect give paclitaxel bavituximab together treat patient Human Epidermal growth factor Receptor 2 ( HER2 ) -negative metastatic breast cancer</brief_summary>
	<brief_title>Paclitaxel Bavituximab Treating Patients With HER2-Negative Metastatic Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine safety , feasibility , tolerability combine paclitaxel weekly bavituximab therapy . SECONDARY OBJECTIVES : I . To describe change pharmacodynamic marker coagulation marker response single agent combine therapy . OUTLINE : Patients receive paclitaxel intravenously ( IV ) day 1 , 8 , 15 bavituximab IV day 1 , 8 , 15 , 22 ( day 15 22 course 1 ) . Courses repeat every 4 week absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Written inform consent obtain Life expectancy least 3 month Histologically cytologically confirm , Her2 negative breast cancer evidence metastatic disease Measurable evaluable disease Response Evaluation Criteria In Solid Tumors ( RECIST ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status = &lt; 2 Adequate hematologic function ( absolute neutrophil count [ ANC ] &gt; = 1,500 cells/uL ; hemoglobin &gt; = 9 g/dL ; platelet &gt; = 100,000/uL = &lt; 500,000/uL ) Adequate renal function ( serum creatinine = &lt; 1.5 mg/dL calculate creatinine clearance &gt; = 60 ml/min ) Adequate hepatic function ( total direct bilirubin = &lt; Upper Limit Normal ( ULN ) , Alk Phos = &lt; 4 x ULN ) Prothrombin time international normalized ratio within institutional normal limit Activated partial thromboplastin time = &lt; 1.5 x ULN New York Heart Association classification I II Female patient must negative urine pregnancy test prestudy ( applicable patient bilateral oophorectomy and/or hysterectomy patient postmenopausal ) Known history bleed diathesis coagulopathy ( e.g. , von Willebrand Disease , Hemophilia ) Any current evidence clinically significant active bleeding Any history significant thromboembolic event ( i.e. , deep vein thrombosis pulmonary thromboembolism ) within last five year requirement ongoing therapy oral parenteral anticoagulant ; central venous catheterrelated thrombosis &gt; 12 month ago low dose anticoagulant maintain patency line allow ; patient take anticoagulant ( e.g. , prophylactic heparin enoxaparin ) require observe washout period 1 week prior study drug infusion Study Day 1 Concurrent hormone therapy ( i.e. , estrogen contraceptive , hormone replacement , antiestrogen ) ; patient take concurrent hormone therapy require observe washout period 2 week prior study drug infusion Study Day 1 Grade 2 high peripheral neuropathy ( e.g. , numbness , tingle , and/or pain distal extremity ) More one prior chemotherapy regimen metastatic disease ( prior adjuvant chemotherapy number prior hormonal therapy allow ) Chemotherapy , immunotherapy radiotherapy within 2 week Study Day 1 recover significant treatmentrelated side effect due agent administer previously ; patient receive nitrosoureas mitomycin C therapy require observe washout period 6 week prior study drug infusion Study Day 1 Allergy polysorbate 80 drug contain polyoxyethylated castor oil ( e.g . cyclosporine ) Symptomatic clinically active Central Nervous System ( CNS ) disease Major surgery within 4 week Study Day 1 Female patient pregnant nurse All patient reproductive potential must agree use appropriate nonhormonal form contraception Uncontrolled intercurrent disease ( e.g. , diabetes , hypertension , thyroid disease ) Any history angina pectoris , coronary artery disease cerebrovascular accident , transient ischemic attack A history condition require antiplatelet therapy ( e.g. , phosphodiesterase inhibitor , adenosine diphosphate receptor antagonist ) exception general cardiovascular prophylaxis aspirin Cardiac arrhythmia require medical therapy Serious nonhealing wound ( include wound heal secondary intention , ulcer , bone fracture ) Requirement chronic daily steroid use Known chronic infection Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>